IDH1 Brain Tumor Mutation Test - IDH1 Immunohistochemistry Test

Immunohistochemical (IHC) assays for IDH1 aim to detect the expression of the mutant isocitrate dehydrogenase 1 (IDH1R132H) variant, which accounts for approximately 90% of all IDH1 mutations in central nervous system tumors. Specific antibodies are used to detect the mutant protein within the nuclei and cytoplasm of tumor cells. This mutation is a characteristic molecular marker for low- and intermediate-grade differentiated gliomas (grades II and III) and secondary gliomas (grade IV).